AMS
American Shared Hospital Services
AMS trails on the overall score without a compensating advantage in the available component scores.
OSCR
Oscar Health, Inc.
OSCR has the edge over AMS overall, supported by stronger fundamentals and lower modeled downside.
AMS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Healthy | |
| Weak |
AMS's revenue and cash flow are currently healthy, but its profitability and balance sheet are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
AMS PE Valuation
AMS has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
AMS Forward outlook
There aren't enough analyst estimates for AMS to show an outlook.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
AMS Earnings Per Share
AMS and OSCR do not have enough comparable growth data to identify a winner.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
AMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $8.4M | +19% |
| Q1 2026 | $7.1M | +16% |
| Q4 2025 | $7.7M | -15% |
| Q3 2025 | $7.2M | +2.5% |
| Q2 2025 | $7.1M | +0.2% |
| Q1 2025 | $6.1M | +17% |
| Q4 2024 | $9.1M | +59% |
| Q3 2024 | $7M | +36% |
AMS's revenue has held roughly level: $8M last quarter, up 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -11% | -3.1 points |
| Q1 2026 | -13% | +8.2 points |
| Q4 2025 | -18% | +2.1 points |
| Q3 2025 | -4.8% | +7.9 points |
| Q2 2025 | -7.7% | -7.7 points |
| Q1 2025 | -21% | -20 points |
| Q4 2024 | -20% | -27 points |
| Q3 2024 | -13% | -14 points |
AMS's operating margin was −11% last quarter, down 3.1 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over AMS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over AMS on profitability, with a higher operating margin.
AMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $2.2M | +$4.5M |
| Q1 2026 | $2.1M | +$3.6M |
| Q4 2025 | $1.3M | +$5.7M |
| Q3 2025 | -$2M | -$1.6M |
| Q2 2025 | -$2.3M | -3347% |
| Q1 2025 | -$1.5M | +$1.5M |
| Q4 2024 | -$4.4M | -$1.2M |
| Q3 2024 | -$407K | -$356K |
AMS's free cash flow has turned positive after two years mostly in the red: $4M over the past year.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over AMS on cash flow, with more consistent year-over-year improvement.
AMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.2% | +147K shares |
| 1 year | +4.4% | +290K shares |
| 3 years | +8.5% | +536K shares |
| 5 years | +18% | +1.1M shares |
| Available history | +16% | +964K shares |
AMS has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
AMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 5.3x | High |
| Q1 2026 | 5.1x | High |
| Q4 2025 | 6.5x | High |
| Q3 2025 | 6.3x | High |
| Q2 2025 | 4.7x | High |
| Q1 2025 | 3.8x | Elevated |
| Q4 2024 | 2.7x | Moderate |
| Q3 2024 | 0.1x | Very low |
AMS's net debt is about 5.3 years of its operating earnings (EBITDA), up from 4.7 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over AMS on leverage, with a lower net debt burden relative to earnings.
AMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.1 | Neutral |
| Stochastic | 11.8 | Oversold |
AMS's weekly RSI is 30 (neutral) and its Stochastic is 12 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
AMS PE vs Healthcare Sector
| Metric | AMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
AMS has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
AMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.28 | 15% below |
| 20 week MA | $1.39 | 22% below |
| 50 week MA | $1.66 | 34% below |
| 100 week MA | $2.15 | 49% below |
| 200 week MA | $2.51 | 57% below |
AMS is in a downtrend: it's below all five of its weekly moving averages, and 57% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over AMS on trend strength, trading above more of its moving averages.
AMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.56 | $2.10 | -18% |
| 2021 | $2.10 | $2.42 | +15% |
| 2022 | $2.42 | $2.81 | +16% |
| 2023 | $2.81 | $2.38 | -15% |
| 2024 | $2.38 | $3.19 | +34% |
| 2025 | $3.19 | $2.14 | -33% |
| 2026 YTD | $2.14 | $1.09 | -49% |
AMS has finished lower in three of the last six years. It's down 49% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over AMS on returns for 2026, with the stronger performance.